Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.8807
−$0.064 · -6.77%
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
Latest quote
$0.8807
−$0.064 · -6.77%
After-hours
$0.89
+$0.0093 · +1.06%
Oct 8, 7:54 PM ET
Regular session · ET · Market data may be delayed.
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
Day range
Current $0.8807
52-week range
Current $0.8807
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
27
Expensive
Sentiment
68
Bullish
Risk
58
Elevated Risk
Momentum
67
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
Day range
Current $0.8807
52-week range
Current $0.8807
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 64K USD | 26.03M USD | — | — | — |
| Gross profit | 64K USD | 26.03M USD | — | — | — |
| Research and development | 37.8M USD | 29.26M USD | 53M USD | 96.63M USD | 80.5M USD |
| Selling, general, and administrative | 20.34M USD | 19.23M USD | 16.05M USD | 20.81M USD | 19.01M USD |
| Operating expenses | 58.14M USD | 48.49M USD | 69.06M USD | 119.32M USD | 98.11M USD |
| Interest income | 2.27M USD | 4.45M USD | 5.2K USD | 1.56M USD | 97.67K USD |
| Interest expense | — | — | — | 21.03K USD | 6.91K USD |
| Depreciation and amortization | 704K USD | 660K USD | 720K USD | 1.03M USD | 634K USD |
| Operating income | −58.07M USD | −22.45M USD | −69.06M USD | −119.32M USD | −98.11M USD |
| Net income | −55.48M USD | −15.63M USD | −62.11M USD | −118.09M USD | −202.27M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM369.61K0.00%78.56B USD0.19%$277.57-0.05%
Vanguard Russell 2000 ETFVTWO193.51K0.00%18B USD0.06%$112.1-0.10%
iShares Russell 2000 Growth ETFIWO108.61K0.00%14.04B USD0.24%$353.47-0.53%
iShares Micro-Cap ETFIWC44.84K0.00%1.33B USD0.60%$182.79-0.31%
Vanguard Russell 2000 Growth ETFVTWG21.67K0.00%1.7B USD0.06%$258.14-0.44%
Vanguard Russell 2000 Value ETFVTWV14.55K0.00%1.4B USD0.06%$186.06+0.59%
iShares Russell 2500 ETFSMMD7.72K0.00%4B USD0.23%$85.96+0.13%
Global X - Russell 2000 ETFRSSL6.51K—1.43B USD0.08%$108.86+0.16%iShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGVanguard Russell 2000 Value ETFVTWViShares Russell 2500 ETFSMMDGlobal X - Russell 2000 ETFRSSLAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
